Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
31 October 2014Website:
http://www.biosig.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
BSGM Latest News
Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.
Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance.
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
BioSig Technologies (NASDAQ: BSGM ) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NASDAQ: NVDA ) Inception program. The Inception program is one that Nvidia uses to select companies with promising developments in the AI and data sciences spaces.
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
What type of business is BioSig Technologies?
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
What sector is BioSig Technologies in?
BioSig Technologies is in the Healthcare sector
What industry is BioSig Technologies in?
BioSig Technologies is in the Medical Devices industry
What country is BioSig Technologies from?
BioSig Technologies is headquartered in United States
When did BioSig Technologies go public?
BioSig Technologies initial public offering (IPO) was on 31 October 2014
What is BioSig Technologies website?
https://www.biosig.com
Is BioSig Technologies in the S&P 500?
No, BioSig Technologies is not included in the S&P 500 index
Is BioSig Technologies in the NASDAQ 100?
No, BioSig Technologies is not included in the NASDAQ 100 index
Is BioSig Technologies in the Dow Jones?
No, BioSig Technologies is not included in the Dow Jones index
When does BioSig Technologies report earnings?
The next expected earnings date for BioSig Technologies is 14 August 2024